Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Recruiting Phase 2 Trials for Ruxolitinib (DB08877)

IndicationStatusPhase
DBCOND0029236 (Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01787487Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmTreatment